

Revision date 30-Jun-2022 Version 1 Page 1/10

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

## 1.1. Product identifier

Product Name Etrasimod

Product Code(s) PF00383

**Synonyms** APD334; PF-07915503

Trade Name: Not established Chemical Family: Not determined

**Etrasimod** 

CAS No 1206123-97-8

REACH Registration Number -

## 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical active

### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc Pfizer Ireland Pharmaceuticals

235 East 42nd Street OSG Building

New York, New York 10017 Ringaskiddy, Co. Cork.

1-800-879-3477 Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

#### 1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

## 2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

**Reproductive toxicity**Category 2 - (H361d) **Chronic aquatic toxicity**Category 1 - (H410)

**OSHA Classification** 

Physical Hazard Combustible Dust

2.2. Label elements

Signal word Warning

Hazard statements H361d - Suspected of damaging the unborn child

H410 - Very toxic to aquatic life with long lasting effects OSHA - May form combustible dust concentrations in air

Precautionary Statements P201 - Obtain special instructions before use

P273 - Avoid release to the environment

Product Name Etrasimod Revision date 30-Jun-2022

Revision date 30-Jun-2022 Version 1

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P391 - Collect spillage P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

Page 2/10



2.3. Other hazards
Other hazards

An Occupational Exposure Value has been established for this substance ( see Section 8 ).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

## 3.1 Substances

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
				[CLP]			
Etrasimod (CAS #: 1206123-97-8)	100	-	Not Listed	Repro.2 (H361d) Aquatic Chronic 1 (H410)	Not Listed	No data available	1

### Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate
No information available

**Additional information** 

- Not Assigned

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## **Section 4: FIRST AID MEASURES**

### 4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Revision date 30-Jun-2022 Version 1

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

Page 3/10

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

Product Name Etrasimod

effects

No data available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

**Hazardous combustion products** 

chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout

gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of the spill or leak. Collect spilled material by a method that controls

dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean spill area

thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

Page 4/10 Revision date 30-Jun-2022 Version 1

## Section 7: HANDLING AND STORAGE

## 7.1. Precautions for safe handling

## Advice on safe handling

Product Name Etrasimod

Restrict access to work area. Avoid open handling. Ground and bond all bulk transfer equipment. Minimize dust generation. Use process containment, local exhaust ventilation or perform work under fume hood/fume cupboard. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store at room temperature in properly labeled containers. Keep away from heat, sparks **Storage Conditions** 

and flames.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical active.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

## 8.1. Control parameters

**Etrasimod** 

Pfizer OEL TWA-8 Hr: 2 µg/m<sup>3</sup>

8.2. Exposure controls

**Engineering controls** Engineering controls should be used as the primary means to control exposures. Use

process containment, local exhaust ventilation, biosafety cabinet, or other engineering

controls to maintain airborne levels.

**Environmental exposure controls** No information available.

Contact your safety and health professional or safety equipment supplier for assistance in Personal protective equipment

> selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the

selection and use of personal protective equipment (PPE).

Wear safety glasses as minimum protection (goggles recommended). (Eye protection Eye/face protection

must meet the standards in accordance with EN166, ANSI Z87.1 or international

equivalent.).

Hand protection Wear impervious disposable gloves (e.g. Nitrile, etc.) as minimum protection (double

recommended). (Protective gloves must meet the standards in accordance with EN374,

ASTM F1001 or international equivalent.).

Wear impervious disposable protective clothing when handling this compound.(Protective Skin and body protection

clothing must meet the standards in accordance with EN13982, ANSI 103 or international

equivalent.).

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is Respiratory protection

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter).

(Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10

Product Name Etrasimod

Revision date 30-Jun-2022 Version 1

or international equivalent.).

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Page 5/10

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical stateSolidColorWhite to light brownOdorNo information available.

Odor thresholdNo information availableMolecular formulaC26 H26 F3 NO3 · C6 H14 N4 O2

Molecular weight 631.7

<u>Property</u> <u>Values</u>

pHMelting point / freezing pointNo data availableNo data available

Boiling point / boiling range
Flash point
No information available

Evaporation rate
No data available
Flammability (solid, gas)
No data available

Flammability Limit in Air
Upper flammability limit:

No data available

Lower flammability limit: No data available

Vapor pressureNo data availableVapor densityNo data availableRelative densityNo data availableWater solubility0.00226 mg/L pH 50.138 mg/L pH 72.59 mg/L pH 9

Solubility(ies)No data availablePartition coefficientNo data availableAutoignition temperatureNo data availableDecomposition temperatureNo data availableKinematic viscosityNo data availableDynamic viscosityNo data available

Dynamic viscosity

No data available
Particle characteristics

Particle Size
Particle Size Distribution
No information available
Explosive properties
No information available

Partition Coefficient: (Method, pH, Endpoint, Value)

Etrasimod

Measured 5 Log D > 6.25 Measured 7 Log D 5.11 Measured 9 Log D 3.48

9.2. Other information

**pKa:** 4.45

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Product Name Etrasimod Revision date 30-Jun-2022

Revision date 50-3dil-2022

## Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

**Reactivity** No data available.

10.2. Chemical stability

**Stability** Stable under normal conditions.

**Explosion data** 

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

**Incompatible materials**As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

## 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** Toxicological properties have not been thoroughly investigated.

Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this

compound may include: headache, contact dermatitis, constipation, and diarrhea.

Acute toxicity

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Skin corrosion/irritation
Respiratory or skin sensitization
STOT - single exposure
STOT - repeated exposure
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

Reproductive toxicity Classification is based on mixture calculation methods based on component data.

Germ cell mutagenicity
Carcinogenicity
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

## Acute Toxicity: (Species, Route, End Point, Dose)

**Etrasimod** 

Mouse Oral Maximally Tolerated Dose 300 mg/kg

Dog Oral LD50 > 1000 mg/kg

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ) Etrasimod

91 Day(s) Mouse Oral 20 mg/kg/day NOAEL Liver, Lungs, Lymphoid tissue

4 Week(s) Rat Oral 150 mg/kg/day NOAEL Liver, Lymphoid tissue, Blood

3 Month(s) Rat Oral 200 mg/kg/day NOAEL Lymphoid tissue, Blood

6 Month(s) Rat Oral 150 mg/kg/day NOAEL Blood, Liver, Lymphoid tissue

4 Week(s) Dog Oral 20 mg/kg/day LOAEL Blood, Lungs, Thymus

3 Month(s) Dog Oral 15 mg/kg/day NOAEL Lungs, Thymus, Liver, Lymphoid tissue

9 Month(s) Dog Oral 15 mg/kg/day NOAEL Heart, Lymphoid tissue

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

PF00383

Page 6 / 10 Version 1

Product Name Etrasimod Revision date 30-Jun-2022

#### Etrasimod

Embryo / Fetal Development Rat Oral 4 mg/kg/day NOAEL Maternal toxicity

Embryo / Fetal Development Rat Oral < 1 mg/kg/day NOAEL Developmental toxicity

Embryo / Fetal Development Rabbit Oral 20 mg/kg/day NOAEL Maternal Toxicity

Embryo / Fetal Development Rabbit Oral 2 mg/kg/day NOAEL Developmental toxicity

Fertility and Embryonic Development Rat Oral (M) 200 / (F) 4 mg/kg/day NOAEL Reproductive toxicity, No effects at

maximum dose

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Etrasimod

Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative In Vitro Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Rat Bone marrow Negative

Carcinogenicity

Not listed as a carcinogen by IARC, NTP or US OSHA.

### 11.2. Information on other hazards

## 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

11.2.2. Other information

Other adverse effects No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Releases to the environment should be avoided. Environmental properties have not been

thoroughly investigated. Classification is based on mixture calculation methods based on

component data

## 12.1. Toxicity

### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

## Etrasimod

Raphidocelis subcapitata (Freshwater alga) OECD NOEC 72 hours 0.089 mg/L Raphidocelis subcapitata (Freshwater alga) OECD ErC50 72 hours > 0.089 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

## Etrasimod

Activated sludge OECD EC50 > 1000 mg/L

## Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

## Etrasimod

Daphnia magna (Water Flea) OECD 21 Day(s) NOEC 0.018 mg/L Survival, Growth

Daphnia magna (Water Flea) OECD 21 Day(s) EC50 > 0.067 mg/L Survival

Daphnia magna (Water Flea) OECD 21 Day(s) LOEC 0.041 mg/L Growth

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 0.016 mg/L Growth, Survival

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) LOEC 0.036 mg/L Survival

## 12.2. Persistence and degradability

### Persistence and degradability

## Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

## Etrasimod

OECD Activated sludge Ultimate (CO2 Evolution) < 60 % After 28 Day(s) Not Ready

## 12.3. Bioaccumulative potential

#### Bioaccumulation

PF00383

Page 7/10 Version 1

Product Name Etrasimod Page 8 / 10
Revision date 30-Jun-2022 Version 1

## Partition Coefficient: (Method, pH, Endpoint, Value)

Etrasimod

Measured 5 Log D > 6.25 Measured 7 Log D 5.11 Measured 9 Log D 3.48

## 12.4. Mobility in soil

## Mobility in soil

Sorption:

Etrasimod (1206123-97-8)

Method Inoculum **End Point** Result OECD Activated sludge Kd (Geometric mean) 3976 OECD Koc (Geometric mean) 12.697 Activated sludge OECD Soil (various) Kd (Geometric mean) 625 Koc (Geometric mean) OECD Soil (various) 54,979

### 12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

## 12.7. Other adverse effects

No information available.

## Section 13: DISPOSAL CONSIDERATIONS

## 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

### The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077

**UN proper shipping name:** Environmentally Hazardous Substance, Solid, n.o.s (etrasimod)

Transport hazard class(es): 9
Packing group: III

Environmental Hazard(s): Marine Pollutant

## 5 kg/5L Exception:

UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not subject to the dangerous goods transportation regulations by any mode:

Page 9/10

Revision date 30-Jun-2022 Version 1

\* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

\* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

Special precautions for user: Not applicable

## Section 15: REGULATORY INFORMATION

## 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Etrasimod

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
EINECS Not Listed

## **European Union**

Product Name Etrasimod

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

#### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

## **Persistent Organic Pollutants**

Not applicable

## Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

#### Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

Chemical Safety Report No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

## Full text of H-Statements referred to under section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child. Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects.

**Data Sources:** Pfizer proprietary drug development information.

Reason for revision New data sheet.

\_\_\_\_\_

Page 10 / 10

Product Name Etrasimod Revision date 30-Jun-2022

Revision date 30-Jun-2022 Version 1

Revision date 30-Jun-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.